Insider · CIK 0001821479
Jason Drew Smith
Files at URGN (UroGen Pharma Ltd.). First filing Jul 30, 2025, latest Sep 9, 2026.
In brief
Jason Drew Smith files SEC Form 4 as officer at URGN (UroGen Pharma Ltd.). Since Jul 30, 2025, Jason Drew Smith has reported 0 open-market buys worth $0 and 4 open-market sells worth $385k, the latest filed on Sep 9, 2026.
A track record needs three past buys with six months of prices behind them; Jason Drew Smith has 0, so none is measured yet.
The newest scored trade: sold $65k of URGN on Sep 8, 2026, filed Sep 9, 2026, scored 16 (weak). In the last 12 months: 0 buys worth $0 and 2 sells worth $212k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
URGN: UroGen Pharma Ltd.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 16Weak | UroGen Pharma Ltd. | $65k 1,519 shares | -3% | - | |
| 24Weak | UroGen Pharma Ltd. | $147k 7,479 shares | -13% | +409% from low-32% from high | |
| 13Weak | UroGen Pharma Ltd. | $29k 1,520 shares | -3% | +445% from low0% from high | |
| 24Weak | UroGen Pharma Ltd. | $144k 7,522 shares | -15% | +381% from low-0% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Sep 9, 2026 | URGN UroGen Pharma Ltd. | 1,519 0.00% of outstanding | $67k | Sep 8, 2026 | none |
| Sep 9, 2025 | URGN UroGen Pharma Ltd. | 1,520 0.00% of outstanding | $29k | Sep 8, 2025 | $144k |
| Jul 29, 2025 | URGN UroGen Pharma Ltd. | 7,522 0.02% of outstanding | $143k | Jul 28, 2025 | none |
Transactions
Every row this insider has filed, 18 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 7, 2026 | URGN UroGen Pharma Ltd. | MOption exercise Ordinary Shares | +3,334 | - | - | 54,660 | 34 d ago |
| Sep 8, 2026 | URGN UroGen Pharma Ltd. | SOpen-market sale Ordinary Shares | -1,519 | $42.54 | $65k | 53,141 | 34 d ago |
| Sep 7, 2026 | URGN UroGen Pharma Ltd. | MOption exercise Restricted Stock Unitsderivative | -3,334 | $0.00 | $0 | 0 | 34 d ago |
| Jan 31, 2026 | URGN UroGen Pharma Ltd. | MOption exercise Ordinary Shares | +5,500 | - | - | 55,472 | Feb 11, 2026 |
| Feb 3, 2026 | URGN UroGen Pharma Ltd. | SOpen-market sale Ordinary Shares | -2,654 | $19.69 | $52k | 52,934 | Feb 11, 2026 |
| Jan 31, 2026 | URGN UroGen Pharma Ltd. | MOption exercise Ordinary Shares | +3,333 | - | - | 58,805 | Feb 11, 2026 |
| Feb 3, 2026 | URGN UroGen Pharma Ltd. | SOpen-market sale Ordinary Shares | -1,608 | $19.69 | $32k | 51,326 | Feb 11, 2026 |
| Jan 31, 2026 | URGN UroGen Pharma Ltd. | MOption exercise Ordinary Shares | +6,667 | - | - | 49,972 | Feb 11, 2026 |
| Feb 3, 2026 | URGN UroGen Pharma Ltd. | SOpen-market sale Ordinary Shares | -3,217 | $19.69 | $63k | 55,588 | Feb 11, 2026 |
| Jan 31, 2026 | URGN UroGen Pharma Ltd. | MOption exercise Restricted Stock Unitsderivative | -5,500 | $0.00 | $0 | 5,500 | Feb 11, 2026 |
| Jan 31, 2026 | URGN UroGen Pharma Ltd. | MOption exercise Restricted Stock Unitsderivative | -3,333 | $0.00 | $0 | 6,667 | Feb 11, 2026 |
| Jan 31, 2026 | URGN UroGen Pharma Ltd. | MOption exercise Restricted Stock Unitsderivative | -6,667 | $0.00 | $0 | 0 | Feb 11, 2026 |
| Jan 31, 2026 | URGN UroGen Pharma Ltd. | AGrant or award Restricted Stock Unitsderivative | +32,609 | $0.00 | $0 | 32,609 | Feb 11, 2026 |
| Sep 7, 2025 | URGN UroGen Pharma Ltd. | MOption exercise Ordinary Shares | +3,333 | - | - | 44,825 | Sep 9, 2025 |
| Sep 8, 2025 | URGN UroGen Pharma Ltd. | SOpen-market sale Ordinary Shares | -1,520 | $19.11 | $29k | 43,305 | Sep 9, 2025 |
| Sep 7, 2025 | URGN UroGen Pharma Ltd. | MOption exercise Restricted Stock Unitsderivative | -3,333 | $0.00 | $0 | 3,334 | Sep 9, 2025 |
| Jul 28, 2025 | URGN UroGen Pharma Ltd. | MOption exercise Ordinary Shares | +16,500 | - | - | 49,014 | Jul 30, 2025 |
| Jul 28, 2025 | URGN UroGen Pharma Ltd. | SOpen-market sale Ordinary Shares | -7,522 | $19.14 | $144k | 41,492 | Jul 30, 2025 |
Questions about Jason Drew Smith
Answered from the filings on this page, as of the latest one.
Is Jason Drew Smith buying or selling?
In the last 12 months Jason Drew Smith reported 0 open-market buys worth $0 and 2 open-market sells worth $212k on SEC Form 4; the latest was sold $65k of URGN on Sep 8, 2026. Grants, option exercises and tax withholding are not counted.
How did Jason Drew Smith's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Jason Drew Smith has 0.
Where does Jason Drew Smith file Form 4?
Jason Drew Smith has filed Form 4 at URGN (UroGen Pharma Ltd.) as General Counsel. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.